Meitheal Company Profile
What is the competitive landscape for MEITHEAL
MEITHEAL has eighty-two approved drugs.
There are four US patents protecting MEITHEAL drugs.
Summary for Meitheal
| US Patents: | 4 |
| Tradenames: | 69 |
| Ingredients: | 68 |
| NDAs: | 82 |
Drugs and US Patents for Meitheal
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meitheal | MILRINONE LACTATE | milrinone lactate | INJECTABLE;INJECTION | 211671-001 | Mar 24, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Meitheal | THIOTEPA | thiotepa | POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL | 216037-001 | Dec 26, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Meitheal | DESMOPRESSIN ACETATE | desmopressin acetate | INJECTABLE;INJECTION | 074888-001 | Oct 15, 1997 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Meitheal | CYTARABINE | cytarabine | INJECTABLE;INJECTION | 206190-001 | Nov 9, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for MEITHEAL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 250 mcg/0.5 mL, 1 mL PFS | ➤ Subscribe | 2012-03-30 |
International Patents for Meitheal Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102597622 | ⤷ Start Trial |
| Brazil | 112019025360 | ⤷ Start Trial |
| Mexico | 2019014354 | ⤷ Start Trial |
| New Zealand | 759953 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Meitheal Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0294114 | 07C0058 | France | ⤷ Start Trial | PRODUCT NAME: NELARABINE, OU L?UN DE SES DERIVES PHYSIOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/403/001 DU 20070822; REGISTRATION NO/DATE AT EEC: EU/1/07/403/001 DU 20070822 |
| 1744764 | 122018000134 | Germany | ⤷ Start Trial | PRODUCT NAME: ZUSAMMENSETZUNG AUS DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
| 1115417 | SPC/GB06/024 | United Kingdom | ⤷ Start Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
| 0275821 | 01C0035 | France | ⤷ Start Trial | PRODUCT NAME: ZOLEDRONIC ACID; NAT REG. NO/DATE: EU/1/01/176/001 20010320; FIRST REG.: LI IKS N 55 463 20001128 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
